AiM  Vol.4 No.13 , October 2014
Automatic Evaluation of Test Strips for Anti-Ganglioside Antibodies in Patients with Guillain-Barré Syndrome Using EUROLineScan Software
Abstract: Campylobacter jejuni infection has been implicated in the pathogenesis of Guillain-Barré syndrome (GBS) due to production of humoral immune response against neural antigens. A case-control study was performed in a tertiary care teaching hospital for the estimation of anti-ganglioside antibodies in GBS patients and their controls. Blood samples were collected from 59 GBS cases, 58 neurological controls (NC) and 60 non-neurological control (NNC) patients for automatic estimation of IgG and IgM antibodies to seven gangliosides using EUROLineScan software. Antibodies of IgG class for GM1 were highly significant in GBS (p = 0.000) and NC (p = 0.031) compared to NNC. However GBS group was not significant (p = 0.413) compared to NC. For GM2 ganglioside, GBS and NC groups were significant (p = 0.000) compared to NNC, but GBS group was not significant (p = 0.999) compared to NC. For GM3 ganglioside, GBS and NC groups were significant (p = 0.000) compared to NNC; but GBS group was insignificant (p = 0.858) compared to NC with similar trend for all other ganglioside antibodies. When IgM class of antibodies was evaluated for GM1, GBS group was not significant (p = 0.604) whereas NC group was significant (p = 0.000) compared to NNC. GBS group was not significant compared to NC (p = 0.011). The trend was the same for GM2 antibodies. For GM3, GBS group was significant (p = 0.010) and NC was near significant (p = 0.055) compared to NNC. However GBS group was not significant (p = 0.808) compared to NC. No groups were significant (p > 0.05) in relation to the remaining gangliosides except for GQ1b where GBS group (p = 0.001) and NC group were significant (p = 0.000) compared to NNC. GBS group was also significant (p = 0.001) compared to NC and NNC. Anti-gangliosides antibodies were present in highly significant levels in the GBS group, though they were also present in the non-paralytic neurological control patients compared to the non-neurological control group.
Cite this paper: Vaishnavi, C. , Behura, C. and Prabhakar, S. (2014) Automatic Evaluation of Test Strips for Anti-Ganglioside Antibodies in Patients with Guillain-Barré Syndrome Using EUROLineScan Software. Advances in Microbiology, 4, 890-898. doi: 10.4236/aim.2014.413099.

[1]   Hughes, R.A.C., Cornblath, D.R. (2005) Guillain-Barré Syndrome. Lancet, 366, 1653-1666.

[2]   Kinnunen, E., Junttila, O., Haukka, J. and Hovi, T. (1998) Nationwide Oral Poliovirus Vaccination Campaign and the Incidence of Guillain-Barré Syndrome. American Journal of Epidemiology, 147, 69-73.

[3]   Rees, J. and Hughes, R. (1994) Guillain-Barré Syndrome after Measles, Mumps and Rubella Vaccine (Letter; Comment). Lancet, 343, 733.

[4]   Newton, N. and Janati, A. (1987) Guillain-Barré Syndrome after Vaccination with Purified Tetanus Toxoid. Southern Medical Journal, 80, 1053-1054.

[5]   Winer, J.B., Hughes, R.A.C., Anderson, M.J., Jones, D.M., Kangro, H. and Watkins, R.P.F. (1998) A Prospective Study of Acute Idiopathic Neuropathy. II. Antecedent Events. Journal of Neurology, Neurosurgery & Psychiatry, 51, 613-618.

[6]   Rhodes, K.M. and Tattersfield, A.E. (1982) Guillain-Barré Syndrome Associated with Campylobacter Infection (Letter). British Medical Journal, 285, 652.

[7]   Kuroki, S., Saida, T., Masafumi, N., et al. (1993) Campylobacter jejuni Strains from Patients with Guillain-Barré Syndrome Belong Mostly to Penner Serogroup 19 and Contain β-N-acetylglucosamine Residues. Annals of Neurology, 33, 243-247.

[8]   Kaldor, J. and Speed, B.R. (1984) Guillain-Barré Syndrome and Campylobacter jejuni: A Serological Study. British Medical Journal, 288, 1867-1870.

[9]   Heidenreich, F. (1998) Autoantibodies Associated with Peripheral Neuropathies. In Conrad, K., et al., Eds., Pathogenic and Diagnostic Relevance of Autoantibodies. Report on the 4th Dresden Symposium on Autoantibodies Held in Dresden on 21-24 October 1998, Pabst Science Publishers, Lengerich.

[10]   Pestronk, A. and Choksi, R. (1997) Multifocal Motor Neuropathy: Serum IgM anti-GM1 Ganglioside Antibodies in Most Patients Detected Using Covalent Linkage of GM1 to ELISA Plates. Neurology, 49, 1289-1292.

[11]   Daune, G.D., Farrer, R.G. and Dalakas, M.C. (1992) Sensory Neuropathy Associated with Monoclonal Immunoglobulin M to GD1b Ganglioside. Annals of Neurology, 31, 683-685.

[12]   Vaishnavi, C., Behura, C., Prabhakar, S., Sharma, A. and Kharbhanda, P. (2013) Anti-Ganglioside Antibodies in Patients with Guillain-Barré Syndrome and Other Neurological Disorders. Indian Journal of Medical Microbiology, 31, 177-179.

[13]   Asbury, A.K. and Cornblath, D.R. (1990) Assessment of Current Diagnostic Criteria for Guillain-Barré Syndrome. Annals of Neurology, 27, S21-S24.

[14]   Meyer, W., Schneider, B., Nobile, Orazio, E., Klotz, M., Schlumberger, W. and Stocker, W. (2002) EUROLINE Anti-Ganglioside-Profile: A New Membrane Test for Detection of Antibodies against Gangliosides. Autoimmunity Reviews, 1, 71.

[15]   Osterman, P.O., Lundemo, G., Pirskanen, R., Fagius, J., Pihlstedt, P. and Siden, A. (1984) Beneficial Effects of Plasma Exchange in Acute Inflammatory Polyradiculoneuropathy. The Lancet, 2, 1296-1298.

[16]   Gorenjac, M. (2004) Clinical and Diagnostic Role of Ganglioside Antibody Testing. Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 15, Article ID: 150309.

[17]   Nobuhiro, Y., Taki, T., Inagaki, F., Kasama, T., Takahashi, M., Saito, K., et al. (1993) A Bacterium Lipopolysaccharide That Elicits Guillain-Barré Syndrome Has a GM1 Ganglioside-Like Structure. The Journal of Experimental Medicine, 178, 1771-1775.

[18]   Yuki, N. and Odada, M. (2005) Ganglioside Mimicry as a Cause of Guillain-Barré Syndrome. Current Opinion in Neurology, 18, 557-561.

[19]   Dikmen, P.Y. and Oge, A.E. (2012) Recurrent GBS with GD1a Anti-Ganglioside Antibodies. Journal of the Peripheral Nervous System, 17, 135-137.

[20]   Taheraghdam, A., Pourkhanjar, P., Talebi, M., Bonyadi, M., Pashapour, A., Sharifipour, E., et al. (2014) Correlations between Cytomegalovirus, Epstein-Barr Virus, Anti-Ganglioside Antibodies, Electrodiagnostic Findings and Functional Status in Guillain-Barré Syndrome. Iranian Journal of Neurology, 13, 7-12.

[21]   Goddard, E.A., Lastovica, A.J. and Argent, A.C. (1997) Campylobacter 0:41 Isolation in Guillain-Barré Syndrome. Archives of Disease in Childhood, 76, 526-528.

[22]   Takahashi, M., Koga, M., Yokoyama, K. and Yuki, N. (2005) Epidemiology of Campylobacter jejuni Isolated Guillain-Barré and Fisher Syndrome in Japan. Journal of Clinical Microbiology, 43, 335-339.

[23]   Koga, M., Gilbert, M., Takahashi, M., et al. (2006) Comprehensive Analysis of Bacterial Risk Factors for the Development of Guillain-Barré Syndrome after Campylobacter jejuni Enteritis. The Journal of Infectious Diseases, 193, 547-555.

[24]   Godschalk, P.C.R., Heikema, A.P., Gilbert, M., et al. (2004) The Crucial Role of Campylobacter jejuni Genes in Autoimmune Antibody Induction. Journal of Clinical Investigation, 114, 1659-1665.

[25]   Saida, T., Kuroki, S., Hao, Q., Nishimura, M., Nukina, M. and Obayashi, H. (1997) Campylobacter jejuni Isolates from Japanese Species with Guillain-Barré Syndrome. The Journal of Infectious Diseases, 176, S129-S134.

[26]   Kaur, U., Chopra, J.S., Prabhakar, S., Radhakrishnan, K. and Rana, S. (1986) Guillain-Barré Syndrome: A Clinical Electrophysiological and Biochemical Study. Acta Neurologica Scandinavica, 73, 394-402.

[27]   Vaishnavi, C. (2001) Campylobacter Enteritis and Extraintestinal Complications. Gastroenterology Today, 4, 189-191.

[28]   Hughes, R.A. and Rees, J.H. (1997) Clinical and Epidemiologic Features of Guillain-Barré Syndrome. The Journal of Infectious Diseases, 176, S92-S98.

[29]   Hadden, R.D. and Gregson, N.A. (2001) Guillain-Barré Syndrome and Campylobacter jejuni Infection. Journal of Applied Microbiology, 90, S145-S154.

[30]   Pradhan, S., Sinha, S., Prasad, N., Jain, D., Pandey, C.M. and Jha, S. (2007) Preceding Infections and Anti-Ganglioside Antibodies in Patients with Guillain-Barré Syndrome: A Single Centre Prospective Case-Control Study. Clinical Microbiology and Infection, 13, 334-337.

[31]   Sharma, A., Lal, V., Modi, M., Vaishnavi, C. and Prabhakar, S. (2011) Campylobacter jejuni Infection in Guillain-Barré Syndrome; A Prospective Case Control Study in a Tertiary Care Hospital. Neurology India, 59, 717-721.

[32]   Schmidt-Ott, R., Schmidt, H., Feldmann, S., Brass, F., Krone, B. and Gross, U. (2006) Improved Serological Diagnosis Stresses the Major Role of Campylobacter jejuni in Triggering Guillain-Barré Syndrome. Clinical and Vaccine Immunology, 13, 779-783.

[33]   Fugimoto, S. and Amako, K. (1990) Guillain-Barré Syndrome and Campylobacter jejuni Infection. The Lancet, 335, 1350.

[34]   McCarthy, N. and Giesecke, J. (2001) Incidence of Guillain-Barré Syndrome Following Infection with Campylobacter jejuni. American Journal of Epidemiology, 153, 610-614.

[35]   Kuwabara, S. (2004) Guillain-Barré Syndrome: Epidemiology, Pathophysiology and Management. Drugs, 64, 597-610.

[36]   Li, C.Y., Xue, P., Tian, W.Q., Liu, R.C. and Yang, C. (1996) Experimental Campylobacter jejuni Infection
in the Chicken: An Animal Model of Axonal Guillain-Barré Syndrome. Journal of Neurology, Neurosurg-
ery Psychiatry, 61, 279-284.